|Bid||77.41 x 1000|
|Ask||77.55 x 900|
|Day's range||74.61 - 78.12|
|52-week range||60.89 - 85.97|
|Beta (5Y monthly)||0.73|
|PE ratio (TTM)||19.98|
|Earnings date||28 Jul 2020 - 03 Aug 2020|
|Forward dividend & yield||2.72 (3.63%)|
|Ex-dividend date||11 Jun 2020|
|1y target est||80.39|
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
President Donald Trump announced that the U.S. was revoking its support for the agency, the latest escalation in a battle that has seen the president accuse the WHO of being too beholden to Beijing.
There have been a lot of moving parts to the development-stage biopharma in recent weeks. In the last week alone, the business has inked a long-term partnership with Gilead Sciences (NASDAQ: GILD) and announced the pricing of a massive public offering of common stock. Earlier this week, Arcus Biosciences inked a 10-year development deal with Gilead Sciences that includes a $175 million up-front payment for Arcus and an additional $200 million equity investment.
European and South Korean authorities are vying for Gilead Sciences' potential COVID-19 treatment, remdesivir, even though the drugmaker has yet to gain regulatory approval in either market and is still ramping up production of the anti-viral drug. Governments are racing to bolster supplies of remdesivir, which U.S. regulators greenlighted this month as a treatment for the novel coronavirus. Foster City, California-based Gilead said it will donate 1.5 million doses of remdesivir, enough to treat at least 140,000 patients, to combat the global pandemic.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced updated results from a single-arm, open-label Phase 1b trial of magrolimab, an investigational anti-CD47 monoclonal antibody, in combination with azacitidine in previously untreated patients with higher-risk myelodysplastic syndrome (MDS) and previously untreated patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy, including patients with TP53-mutant AML, a high unmet need population. Results continue to support the clinical activity of magrolimab and azacitidine. The data were presented during an oral session at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting held from May 29-31 (Abstract 7057).
Kite, a Gilead Company (Nasdaq: GILD), today announced results from an interim analysis of ZUMA-5, a global, multicenter, single-arm, open-label Phase 2 study evaluating Yescarta® (axicabtagene ciloleucel) in adult patients with relapsed or refractory indolent (slow growing) non-Hodgkin lymphoma (NHL) after at least two prior lines of therapy. After a single infusion of Yescarta, 93 percent of patients (n=96 evaluable for efficacy) responded, with 80 percent of patients achieving a complete response (CR) as assessed by an independent review committee. The data were presented in an oral session during the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting held from May 29-31 (Abstract 8008). The presentation has also been selected for a Highlights of the Day session as part of ASCO’s 2020 Virtual Scientific Program on Saturday, May 30 at 11:30 am ET. The Highlights sessions recap the most impactful science from the oral sessions.
Gilead announced "top-line" findings from the trial on April 29. Gilead's trial involved 397 patients hospitalized with severe COVID-19, most of whom were not on ventilators. Gilead said the results should not be interpreted as indicating that the shorter duration worked better since evidence of improved outcomes occurred early on, leading investigators to attribute the difference to imbalances in patient status at enrollment.
(Bloomberg) -- YouTube’s battle against Covid-19 misinformation is causing collateral damage as the world’s largest online video service struggles to pick up on nuances of an increasingly complex and political topic.Since January, California pulmonologist Roger Seheult has posted regular medical lectures about the novel coronavirus on his YouTube channel, MedCram. His audience jumped to more than 700,000 subscribers. But as the virus spread in the spring, YouTube deleted five of the MedCram clips, including two about the controversial drug hydroxychloroquine and one about Remdesivir, an experimental Covid-19 treatment developed by Gilead Sciences Inc.Seheult appealed the decisions. Viewer complaints flooded in; one fan started a petition demanding YouTube stop “censoring” the footage. For Seheult, YouTube’s new rules were applied without explanation. “It’s like you’re in a hockey game,” he said. “And you keep getting called for penalties, but you don’t know what the penalties are.”According to YouTube, the referee made a mistake.“With the massive volume of videos on our site, sometimes we make the wrong call,” a YouTube spokesman said on Wednesday after Bloomberg News reached out for comment. “When it’s brought to our attention that a video has been removed mistakenly, we act quickly to reinstate it.” The five MedCram videos are back on the site now.The incident is another flash point in the debate over the role of internet gatekeepers like YouTube and its parent, Alphabet Inc.’s Google. On Wednesday, U.S. President Donald Trump railed against social-media companies after Twitter Inc. fact-checked some of his tweets. He’s also preparing an executive order that could limit liability protections from the largest user-generated networks: Twitter, Facebook Inc. and YouTube.At the same time, Democratic lawmakers have chastised YouTube for not removing conspiracy theories about the pandemic swiftly enough. In a letter to House Intelligence Chairman Adam Schiff, released on Thursday, YouTube Chief Executive Officer Susan Wojcicki wrote that the company’s automated systems detected a majority of “dangerous or misleading” videos about the virus. “The complex nature of misinformation online presents a number of challenges for platforms such as YouTube and I welcome your suggestions as to what we can do better,” she added.In addition to this political pressure, YouTube has been inundated with virus videos, while the pandemic has disrupted its contract workforce doing content moderation.“YouTube has a really tough job,” said Kyle Allred, MedCram’s co-founder and producer. “But the reality is: YouTube’s the second biggest search engine in the world. If our videos aren’t on YouTube, we don’t have the benefit of reaching as many people.”During the pandemic, YouTube has aggressively moderated virus videos after years of a more laissez-faire approach. The company has pulled thousands of clips for promoting misleading information or advice that conflicts with public health agencies. To filter footage, YouTube relies on viewers flagging videos, automated software and legions of human moderators.At the best of times, the system is sometimes heavy-handed or too lenient. In March, the company said it had to limit its use of human moderators, due to remote work limitations, and would lean more on machines to make decisions.YouTube’s challenge has grown even harder as medical videos pour onto the site and the debate about the pandemic response evolves from a mostly scientific discussion into a political fight.Trump has said he took hydroxychloroquine for about two weeks and the president has promoted it as a possible coronavirus therapy, despite an outcry from medical professionals about its unproven efficacy and potential side effects.At times, YouTube has filtered out sham science, such as videos promoting fake cures for Covid-19. More controversially, it has acted against doctors departing from public health advice. In April, YouTube removed videos by two doctors in Bakersfield, California, who used their YouTube channel to call for an end to social-distancing policies.Seheult, the pulmonologist, said his videos are nothing like that. Instead, MedCram clips dissect medical studies and early research, called preprints, related to the virus. Seheult narrates the findings and statistics -- low-key footage that, thanks to the pandemic, now draws a large audience.It seems Seheult was struck by YouTube’s algorithms scanning footage about Covid-19 cures. All five removed videos focused on potential treatments. YouTube says it relies on medical advisers and public agencies for guidance on how to handle videos about health issues. Yet the scientific consensus on some Covid-19 treatments is still taking shape. A study in The Lancet medical journal, released last week, linked hydroxychloroquine with increased risk of death and heart ailments.The YouTube spokesperson declined to cite the reason why the MedCram videos were initially removed, beyond noting that it was a mistake.The team behind MedCram is happy to have their work back on the world’s biggest video site. But they still feel frustrated with the minimal communication from YouTube. “We’re grateful to have our website MedCram.com where we don’t have to worry about censorship,” said Allred.(Updates with information on Trump executive order, YouTube CEO letter to Congress in eighth and ninth paragraphs.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Zacks.com featured highlights include: TakeTwo Interactive Software, Gilead Sciences and Regeneron Pharmaceuticals
Diodes Incorporated (Nasdaq: DIOD) today announced the AP7353 low dropout regulator, which offers a high power supply rejection ratio (PSRR) in a small package, meeting the need for voltage regulation in noise-sensitive, battery-operated devices such as wearables, portables, and connected sensors.
Unlike most penny stocks, these three companies are leaders in their respective industries and could provide market-beating returns for a while.
These three stocks are leaders in the fight against COVID-19 and have compelling growth prospects beyond their coronavirus programs.
Gilead Sciences (NASDAQ: GILD) and Arcus Biosciences (NYSE: RCUS) have signed a 10-year agreement to co-develop and co-commercialize the next-generation cancer therapeutics in Arcus' pipeline. The agreement also gives Gilead an equity position in the small-cap, clinical-stage biotech company. Shares of Gilead inched up 0.7% Wednesday on the news, but investors apparently thought Arcus didn't drive a hard enough bargain -- its stock fell 13% to $29.
Diodes Incorporated (Nasdaq: DIOD) today announced the introduction of the PI3WVR626, a MIPI® D-PHY/C-PHY 2:1 switch that enables a single host device to interface with two MIPI compliant modules, helping engineers optimize the design of multi-camera cell phones and other personal computing devices.
Gilead Sciences, Inc. (NASDAQ: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapeutics, announced today that the companies have entered into a 10-year partnership to co-develop and co-commercialize current and future therapeutic product candidates in Arcus’s pipeline. The agreement will also provide ongoing funding to support Arcus’s research and development programs.
Novavax announced it would begin human trials for its coronavirus vaccine, while COVID-19 engulfs Brazil.
Abbott Labs (NYSE: ABT) made headlines in late March when the FDA gave emergency use authorization (EUA) for the company's COVID-19 test that runs on its ID NOW platform. Abbott also announced interim results last week from a clinical study in urgent care clinics that showed high levels of sensitivity for positive results and specificity for negative results.
The coronavirus pandemic accelerated a wellness renaissance among consumers as shelter in place orders took effect, based on some of the sales trends seen by companies including Ro.
These biotech companies are both infectious disease experts and are likely to remain in the forefront when it comes to coronavirus treatment.